Genentech and OSI Pharmaceuticals will pay a $67 million settlement related to a lung cancer drug.

Story highlights

Genentech and OSI Pharmaceuticals settled a suit related to the lung cancer drug Tarceva

A whistle-blower lawsuit claims the drug was sold for a broader patient population than it could treat

CNN  — 

Two pharmaceutical companies owe $67 million as a part of a federal court settlement over allegations that they made misleading claims about a drug used to treat lung cancer.

The companies are Genentech, which is based in South San Francisco and is now a part of the Roche Group, and Farmingdale, New York-based OSI Pharmaceuticals, which is now a part of Astellas Pharma. They were taken to court when a former Genentech employee alleged that the company provided doctors and medical professionals with misleading information about the drug.

There is no finding in this ruling that the companies are legally liable for the claims.

The drug, Tarceva, is approved to treat non-small-cell lung cancer and advanced-stage pancreatic cancer.

The companies led doctors to believe that the drug would work in a broad patient population, according to the complaint, when, in fact, “there was little evidence to show that Tarceva was effective” to treat certain patients with non-small-cell lung cancer, according to a news release from the Department of Justice. It worked only on a narrower patient population, including patients who had never smoked and people who carried a particular mutation in a protein that is involved in the spread and growth of cancer cells.

The complaint also suggests that the company failed to report all the adverse events related to the drug. That could mean doctors were choosing to use it to treat lung cancer patients instead of a treatment that has been proved to have more success.

The Department of Justice said the company made these claims to medical professionals between January 2006 and December 2011.

The whistle-blower in the case was a former Genentech employee, Brian Shields.

Shields was a product manager who tried to bring the problem to the attention of his managers. Instead of receiving an appropriate response, the complaint suggests, he faced retaliation for doing so and was told he was “not a team player.”

Join the conversation

  • See the latest news and share your comments with CNN Health on Facebook and Twitter.

    Under the False Claims Act, Shields is entitled to about $10 million of the settlement. Another $62.6 million will go to the federal government. State Medicaid programs will get $4.4 million.

    “Pharmaceutical companies have a responsibility to provide accurate information to patients and health care providers about their prescription drugs,” said a statement from the head of the Justice Department’s civil division, Benjamin C. Mizer. “The Department of Justice will hold these companies accountable that mislead the public about the efficacy of the products.”